InMed Pharmaceuticals Inc. has reported its financial results for the first quarter of fiscal 2027, which ended on September 30, 2026. The announcement comes as the company approaches a significant milestone with its proposed merger with Mentari Therapeutics, a privately held biotechnology firm specializing in migraine prevention therapies.

Eric A. Adams, President and CEO of InMed, emphasized the importance of this merger, stating, "We are approaching an important milestone in our proposed merger with Mentari Therapeutics, with our annual general and special meeting scheduled for November 4, 2026." The merger is expected to create a combined entity that will operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market.

InMed's financial report indicates a shift in focus as the company prepares for the merger. The company reported research and development expenses of $0.2 million for the quarter, a decrease from $0.6 million during the same period last year. This reduction is attributed to a decrease in operational activity as the merger progresses.

Background

InMed Pharmaceuticals Inc. is a pharmaceutical company based in Vancouver, British Columbia, specializing in developing proprietary small molecule drug candidates. The company operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. InMed is listed on the Nasdaq under the ticker symbol INM.

Recent filings include a Form 8-K on November 3, 2026, which details the company's financial results and the ongoing merger process. The company has also filed a Form 10-Q on the same day, along with other relevant documents leading up to the merger.

What the Filing Says

The recent filing reveals that InMed is working towards completing its merger with Mentari Therapeutics, which is expected to close in the fourth quarter of 2026. The merger will allow InMed shareholders to participate in the development of Mentari's migraine prevention pipeline. Additionally, the company is pursuing opportunities to realize value from its legacy pharmaceutical assets through a proposed contingent value rights structure.

Impact

This merger could significantly impact InMed's future operations and its position within the pharmaceutical preparations industry. The combined resources and expertise from both companies may enhance their ability to develop innovative therapies, particularly in the migraine prevention market. Shareholders will be invited to vote on the merger and related proposals during the upcoming annual general and special meeting.

What's Next

The annual general and special meeting is scheduled for November 4, 2026, where shareholders will vote on the merger and other proposals. InMed's Board of Directors has recommended that shareholders vote in favor of the merger, which is critical for the company's future direction.

InMed's latest financial statements and additional details regarding the merger can be accessed through their official channels, including their website and the SEC's database, under the accession number 0001062993-26-005723.